Atrasentan in Treating Patients With Prostate Cancer

Completed · Phase 3

Conditions studied: Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate cancer that has not responded to hormone therapy.

Key facts

Study ID

NCT00046943

Run by

Abbott

Starts

2002-09-01

Last updated by the study team

2011-02-21

Who can join

Age: 19 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.